However, a recent study showed no correlation between SLFN11 expression and olaparib activity in breast cancer cell lines and PDX models (Winkler et al. 2021), stressing the need for cancer-specific experiments to examine SLFN11 as a biomarker. This evidence concerns the gene SLFN11 and breast carcinoma.